Post Profile






The maker of EpiPen has agreed to pay the government $465 million after allegedly overcharging for the medicine

Mylan, the marker of the EpiPen, has agreed to pay the federal government a $465 million settlement after it allegedly overcharged government healthcare agencies for the medicine, according to a release from the firm. Mylan had underpaid Medicare and Medicaid by classifying the EpiPen as a generic drug. Generic drugs are subject to a 13% rebate from the maker to Medicaid and Medicare, rather than a 23.
read more

share

Related Posts


CONFIRMED: The maker of EpiPen overcharged the government and lawmakers are furious

Business & Finance : Business Insider: Clusterstock

The Centers for Medicare & Medicaid Services (CMS) confirmed to lawmakers that Mylan, the drug company that makes EpiPen, has been overcharging the government for the life-saving allergy medication. And naturally, lawmakers are furi...

Mylan to pay $465 million over Medicaid pricing of EpiPen

Business & Finance : Mashable: Business

Mylan will pay the Department of Justice $465 million in a settlement over its pricing and classification of the EpiPen through Medicaid, the pharmaceutical company announced Friday.  Mylan, which came under fire this summer for sys...

Mylan to pay $465M settlement over EpiPen

Business & Finance : USAToday: Money

EpiPen maker Mylan agreed to pay $465 million in a settlement with federal regulators over its pricing practices        

Mylan to pay $465-million settlement over Medicaid EpiPen rebates

Business & Finance : LA Times: Business

Mylan will pay $465 million to settle allegations that it overbilled Medicaid for its life-saving EpiPen allergy injection. The federal government says EpiPen is a branded drug, which means Mylan should have been paying a far higher...

EpiPen Maker Mylan Will Pay $465 Million to Settle Medicaid Overcharging Case

Business & Finance : DealBook

Mylan said the settlement, after the government had said it improperly classified EpiPen as a generic drug, did not imply any admission of wrongdoing.

Comments


Copyright © 2016 Regator, LLC